share_log

BioAffinity Technologies Sees Accelerating Growth Of Physician Practices Ordering CyPath Lung Tests

Benzinga ·  Jun 12 20:11

Sales of CyPath Lung tests, onboarding of pathology practices ahead of forecasts

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today reported 139% growth in the number of pulmonology practices and physicians offering CyPath Lung to patients since Jan. 1, 2024. CyPath Lung is a noninvasive test to detect early-stage lung cancer.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment